UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 71-0869350 (State or Other Jurisd ...

Amicus Therapeutics Inc. (NASDAQ:FOLD) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Bradley Campbell - President, Chief Executive Officer Sébastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Daphne Quimi - Chief Financial Officer Andrew Faughnan - Vice President, Investor Relations Conference Call Participants Malcolm Kuno - JP Morgan Ellie Merle - UBS Joseph Schwartz - SVB Securities Athena - Cowen Dae Gon Ha - Stifel Kristen Kluska - Cantor ...

For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 71-0869350 (State or Other Juris ...

Amicus Therapeutics. (NASDAQ:FOLD) Q4 2022 Earnings Conference Call March 1, 2023 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President, Chief Executive Officer Sébastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Daphne Quimi - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Ritu Baral - Cowen Tazeen Ahmad - Bank of America Ellie Merle - UBS Joseph Schwartz - SVB Securities Dae Gon Ha - St ...

Forward-Looking Statements In addition to financial information prepared in accordance with U.S. GAAP, this press release also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the informa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 71-0869350 (State or Other Jurisdicti ...

Amicus Therapeutics Inc. (NASDAQ:FOLD) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Bradley Campbell - President, Chief Executive Officer Sébastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Daphne Quimi - Chief Financial Officer Andrew Faughnan - Executive Director, Investor Relations Conference Call Participants Ritu Baral - Cowen Anupam Rama - JP Morgan Joseph Schwartz - SVB Securities Tazeen Ahmad - Bank of America Sarah - UBS Dae Gon ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Andrew Faughnan - Senior Director, IR Bradley Campbell - CEO, President & Director Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Daphne Quimi - CFO Conference Call Participants Anupam Rama - JPMorgan Chase & Co. Ritu Baral - Cowen and Company Joseph Schwartz - SVB Securities Dae Gon Ha - Stifel Zhiqiang Shu - Berenberg Ellie Merle - UBS Operator Goo ...

| --- | --- | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2Q22 Financial Results Conference Call & Webcast At the Forefront of Therapies | | | | | | | | | August 4, 2022 for Rare Diseases | | | | | | | | 2 Forward-Looking Statements This presentation contains "forward-looking statements" ...

| --- | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Corporate Overview At the Forefront of Therapies for Rare Diseases | | | | | | | | May 2022 | | | | | | | 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ...